NICE error means breathing room for Lilly's Alimta
This article was originally published in Scrip
Executive Summary
Lilly has won a little extra breathing room to convince NICE, the health technology appraisal institute for England and Wales, to recommend its lung cancer drug Alimta (pemetrexed) after the institute made a procedural error in the appraisal process. NICE has had to retract previous negative final draft guidance and publish new draft recommendations rather than proceeding to final guidance